Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 592 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo, vehicle control Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris

NCT02160678
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, Tazarotene Cream, 0.1 %, Tazorac Cream, 0.1%
Drug
Lead sponsor
G & W Laboratories Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,741 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Arlington Hts., Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Results available

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)

NCT01014403
View directory record Official record
Conditions
Venous Thromboembolism, Traumatic Brain Injury
Interventions
enoxaparin, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Dallas, Texas • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

NCT01986361
View directory record Official record
Conditions
Acute Pharyngitis, Sore Throat
Interventions
flurbiprofen, placebo
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

A Study of RX-10045 in the Treatment of Dry Eye Disease

NCT01675570
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RX-10045, Vehicle for RX-10045
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

NCT03850483
View directory record Official record
Conditions
Psoriasis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905
View directory record Official record
Conditions
Left Ventricular Insufficiency
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 4 Interventional

Evaluation of Tear Film Quality and Stability in Subjects With Dry Eye Disease Using OC-01 (Varenicline Solution) Nasal Spray 0.03 mg as Compared to Vehicle Control Nasal Spray

NCT05514041
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Varenicline solution, Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Drug
Lead sponsor
Stephenson Eye Associates
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Venice, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

NCT03088605
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

NCT05332366
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Delgocitinib cream, Delgocitinib cream vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 30, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

NCT04806503
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLPG Topical Gel 1%, Clindamycin, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 4 Interventional

Quality of Life Study in Adults With Facial Eczema

NCT00120302
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
View directory record Official record
Conditions
Health
Interventions
INO-8875, Placebo control
Drug · Other
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 30, 2026, 11:59 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy

NCT00871208
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Altabax (R), Vehicle and Locoid lipocream (R)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
9 Months to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT02485717
View directory record Official record
Conditions
Scabies
Interventions
spinosad topical suspension, 0.9%, Placebo
Drug · Other
Lead sponsor
ParaPRO LLC
Industry
Eligibility
4 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Elk Grove, California • Kissimmee, Florida • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

NCT00422188
View directory record Official record
Conditions
Lipoma
Interventions
Deoxycholic Acid Injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 30, 2026, 11:59 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Sep 30, 2026, 11:59 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 30, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

Relieving Acute Pain (RAP) Study: A Pilot Study

NCT03426137
View directory record Official record
Conditions
Trauma, Opioid Use, Spine Fusion
Interventions
Oxycodone, Ketorolac, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 30, 2026, 11:59 AM EDT
Completed Phase 4 Interventional Results available

CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial

NCT00847912
View directory record Official record
Conditions
Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Skin Neoplasms, Skin Diseases, Neoplasms, Basal Cell, Neoplasms, Squamous Cell, Carcinoma
Interventions
5-fluorouracil, Placebo, vehicle control
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
954 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Sep 30, 2026, 11:59 AM EDT